The global antiviral drugs market is expected to reach a
value of USD 69.2 billion by 2025, based on a new report by Grand View
Research, Inc. According to the WHO, cases of viral infections increase by more
than 1 million each year with around 357 million patients already suffering
from one of the four Sexually Transmitted Infections (STIs), such as Acquired
Immunodeficiency Syndrome (AIDS).
Introduction of efficient
antiviral drugs with benefits such as rapid action, increased sensitivity, and
lower adverse effects is expected to serve this market as a high-impact
rendering driver over the forecast period. For instance, Gilead Sciences
introduced an FDA-approved drug-Genvoya-in 2016 for treatment of AIDS patients
who have previously faced adverse effects, such as bone loss and kidney
dysfunction.
Low levels of hygiene, growing
geriatric population, and increasing awareness through government campaigns are
other drivers resulting in high acceptance of antiviral drugs in developing
countries.
Browse full research report on Antiviral Drugs Market: http://www.grandviewresearch.com/industry-analysis/antiviral-drugs-market
Further Key Findings From
the Study Suggest:
- Reverse transcriptase inhibitors held the largest
share by mechanism of action owing to availability of wide range of
product portfolio and presence of new molecules in clinical trials
- Nucleotide inhibitors are estimated to grow at
lucrative rate due to introduction of blockbuster molecules for treatment
of Hepatitis C Virus (HCV) infections
- Generic drugs are anticipated to witness significant
CAGR of over 7.0% over the forecast period as result of patent expiry of
blockbuster drugs used for treatment of HIV and HCV
- Branded drugs will hold dominant position in 2025 by
drug type due to brand loyalty of healthcare professions despite patent
expiration and high price associated with these molecules
- HIV/AIDS held the dominant share in 2015. High
prevalence of HIV infections and presence of favorable government
initiatives for curbing them are key factors for high revenue of this
segment
- Hepatitis on the other hand is anticipated to witness
flourishing growth over the forecast period owing to introduction of new
molecules and approval of novel combination treatments
- North America was the dominant regional market in
2015. High market share is associated with established R&D
infrastructure and growing drug development initiatives
- Asia Pacific region is anticipated to exhibit fastest
regional growth. Local presence of key generic players and growing
healthcare infrastructure in this region are key factors for growth
- Some of the key players of this market include Gilead
Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline; Bristol-Myers-Squibb;
AbbVie; Johnson & Johnson; and Merck & Co. Other generic players
in this market are Aurobindo Pharma, Cipla, and Dr Reddy’s
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the antiviral drugs market
based on mechanism of action, type, application, and region:
Antiviral Drugs Mechanism of Action Outlook (Revenue, USD
Billion; 2014 - 2025)
- Nucleotide
Polymerase Inhibitors
- Reverse
Transcriptase Inhibitors
- Protease
Inhibitors
- Others
Antiviral Drugs Type Outlook (Revenue, USD Billion;
2014 - 2025)
- Generic
- Branded
Antiviral Drugs Application Outlook (Revenue, USD
Billion; 2014 - 2025)
- HIV
- Hepatitis
- Herpes
Simplex Virus
- Influenza
- Others
Antiviral Drugs Regional Outlook (Revenue, USD Million,
2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- China
- Japan
- India
- Latin
America
- Mexico
- Brazil
- MEA
- South
Africa
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of California
and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
No comments:
Post a Comment